CVS Health Corporation (New York Stock Exchange:CVS)
| Market Cap | 119.55B+13.4% |
| Revenue (ttm) | 415.09B+7.4% |
| Net Income | 4.91B+8.3% |
| EPS | 3.78+5.6% |
| Shares Out | 1.28B |
| PE Ratio | 24.40 |
| Forward PE | 10.97 |
| Dividend | $2.66(2.85%) |
| Ex-Dividend Date | Oct 22, 2026 |
| Volume | 4,601,442 |
| Open | 94.00 |
| Previous Close | 94.48 |
| Day's Range | 93.22 - 94.40 |
| 52-Week Range | 69.51 - 110.68 |
| Beta | 0.60 |
| Analysts | Buy |
| Price Target | 111.25(+19.02%) |
| Earnings Date | Nov 4, 2026 |
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
About CVS
CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.
$CVS stock is featured in our Congress Trading, and Insider Trades datasets.
→ All Stock ListsCongress Trading
Recent trades of CVS by members of U.S. Congress
| Politician | Type | Traded |
|---|---|---|
| Alan ArmstrongSenate / R | Purchase$1.00K – $15.00K | Mar 27, 2026 |
| John BoozmanSenate / R | Purchase$1.00K – $15.00K | Jan 29, 2026 |
| Michael T. McCaulHouse / R | Sale$15.00K – $50.00K | Jan 13, 2026 |
| Michael T. McCaulHouse / R | Sale$100.00K – $250.00K | Apr 10, 2025 |
| French HillHouse / R | Sale$15.00K – $50.00K | Jan 31, 2025 |
| Gilbert Ray CisnerosHouse / D | Purchase$1.00K – $15.00K | Jan 24, 2025 |
| Gilbert CisnerosHouse / D | Purchase$1.00K – $15.00K | Jan 24, 2025 |
| Gilbert Ray CisnerosHouse / D | Purchase$1.00K – $15.00K | Jan 23, 2025 |
Recently reported changes in CVS holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by CVS's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
CVS Estimated quarterly lobbying spending
Source: U.S. Senate LDA
CVS Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Pharmacy | $60.83B | 28.75% |
| Health Services | $45.39B | 21.46% |
| Health Care Benefits | $37.00B | 17.49% |
| Premiums | $35.12B | 16.60% |
| Pharmacy & Consumer Wellness | $23.05B | 10.90% |
| Front Store | $5.41B | 2.56% |
| Other | $4.11B | 1.94% |
| Net investment income (loss) | $641.00M | 0.30% |
| Corporate/ Other | $13.00M | 0.01% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New CVS patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to CVS from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in CVS
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $3.48B |
| VOOVanguard S&P 500 ETF | $2.88B |
| IVViShares Core S&P 500 ETF | $1.60B |
| SPYState Street SPDR S&P 500 ETF | $1.48B |
| VTVVanguard Morningstar Value ETF | $1.04B |
| XLVState Street Health Care Select Sector SPDR ETF | $875.54M |
Estimated from each fund’s disclosed top holdings × AUM
CVS Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from CVS’s recent data — informational, not investment advice
Recent Insider Activity
No Form 4 filings in the last 90 days.